Attached files
file | filename |
---|---|
8-K - MusclePharm Corp | tit_8k.htm |
EX-2.1 - MusclePharm Corp | tit_ex2-1.htm |
EX-99.1 - MusclePharm Corp | tit_ex99-1.htm |
EXHIBIT
99.2
Tone in
Twenty
Introduction
to Pro Forma Combined Financial Statements
(Unaudited)
The
following unaudited pro forma financial statements are presented to illustrate
the estimated effects of the Securities Exchange Agreement ("Exchange
Transaction") between Tone in Twenty and Muscle Pharm, LLC ("Muscle Pharm"),
dated February 1, 2010 on our historical financial position and results of
operations. We have derived our historical financial data from our
audited financial statements as of and for the year ended August 31, 2009, and
from our unaudited financial statements as of and for the period ended November
30, 2009. We have derived Muscle Pharm's financial data from its
audited financial statements as of and for the period from inception (April 22,
2008) to December 31, 2008, and its unaudited financial statements as of and for
the period ended September 30, 2009.
The
unaudited pro forma combined balance sheet as of November 30, 2009 assumes the
Exchange Transaction was consummated on November 30, 2009. The
information presented in the unaudited pro forma combined financial statements
does not purport to represent what the financial position or results of
operations would have been had the Exchange Transaction occurred as of November
30, 2009, nor is it indicative of future financial position or results of
operations. You should not rely on this information as being
indicative of the historical results that would have been achieved dad the
companies always been combined, or the future result that the combined company
will experience after the Exchange Transaction is consummated.
The pro
forma adjustments are based upon available information and certain assumptions
that the Company believes is reasonable under the circumstances. The
unaudited pro forma financial statements should be read in conjunction with the
accompanying notes and assumptions and the historical financial statements of
Tone in Twenty and Muscle Pharm, LLC.
1
Tone in
Twenty
Pro Forma
Combined Balance Sheets
(Unaudited)
Pro
Forma Adjustments (1)
|
||||||||||||||||||||||||
Tone
in Twenty
|
Muscle
Pharm LLC
|
(2 | ) | (3 | ) | (4 | ) |
Pro
Forma Combined
|
||||||||||||||||
November
30, 2009
|
September
30, 2009
|
|||||||||||||||||||||||
Assets:
|
||||||||||||||||||||||||
Current
assets:
|
||||||||||||||||||||||||
Cash
|
$ | 1,562 | 451 | $ | 2,013 | |||||||||||||||||||
Accounts
receivable
|
10,358 | 10,358 | ||||||||||||||||||||||
Inventory
|
1,677 | 1,677 | ||||||||||||||||||||||
Deposits
on product
|
- | - | ||||||||||||||||||||||
Prepaid
expenses and other current assets
|
2,387 | 2,387 | ||||||||||||||||||||||
Total
current assets
|
1,562 | 14,873 | 16,435 | |||||||||||||||||||||
Fixed
assets, net
|
15,932 | 15,932 | ||||||||||||||||||||||
Patent
|
- | - | ||||||||||||||||||||||
Website,
net
|
7,960 | 7,960 | ||||||||||||||||||||||
Seurity
deposits
|
1,207 | 1,207 | ||||||||||||||||||||||
Total
assets
|
$ | 1,562 | 39,972 | $ | 41,534 | |||||||||||||||||||
Liabilities
and Stockholder's Equity (Deficit):
|
||||||||||||||||||||||||
Current
liabilities:
|
||||||||||||||||||||||||
Accounts
payable
|
1,670 | 355,149 | 356,819 | |||||||||||||||||||||
Accrued
interest
|
4,499 | 4,499 | ||||||||||||||||||||||
Overdrawn
bank accounts
|
17,645 | 17,645 | ||||||||||||||||||||||
Customer
deposits
|
112,731 | 112,731 | ||||||||||||||||||||||
Other
short term borrowings
|
25,000 | 25,000 | ||||||||||||||||||||||
Due
to related parties
|
73,528 | 73,528 | ||||||||||||||||||||||
Notes
payable
|
30,000 | 30,000 | ||||||||||||||||||||||
Convertible
notes payable
|
297,500 | 297,500 | ||||||||||||||||||||||
Total
current liabilities
|
1,670 | 891,052 | 917,722 | |||||||||||||||||||||
Equity:
|
||||||||||||||||||||||||
Convertible
preferred stock, $0.001 par value,
|
||||||||||||||||||||||||
5,000,000
shares authorized, 83,333 shares issued and outstanding
|
83 | 83 | ||||||||||||||||||||||
Common
stock, $0.001 par value,
|
||||||||||||||||||||||||
195,000,000
shares authorized, 437,500 shares issued and outstanding (26,070,834
shares issued and outstanding combined)
|
438 | 26,000 | (367 | ) | 26,071 | |||||||||||||||||||
Additional
paid-in capital
|
1,027,349 | 536,000 | (24,633 | ) | (1,027,978 | ) | 510,738 | |||||||||||||||||
Deficit
accumulated during the development stage
|
(1,027,978 | ) | 1,027,978 | - | ||||||||||||||||||||
Accumulated
deficit
|
(1,413,080 | ) | (1,413,080 | ) | ||||||||||||||||||||
Member's
deficit
|
(851,080 | ) | (562,000 | ) | 1,413,080 | - | ||||||||||||||||||
Total
equity
|
(108 | ) | (851,080 | ) | (876,188 | ) | ||||||||||||||||||
Total
Liabilities and Stockholders' Equity (Deficit)
|
$ | 1,562 | 39,972 | $ | 41,534 |
See notes
to pro forma combined financial statements
2
Tone in
Twenty
Pro Forma
Combined Statement of Operations
(Unaudited)
Year
ended August 31, 2009
|
From
Inception (April 22, 2008) to December 31, 2008
|
Pro
Forma Adjustments (1)
|
||||||||||||||||||||||
Tone
in Twenty
|
Muscle
Pharm LLC
|
(2 | ) | (3 | ) | (4 | ) |
Pro
Forma Combined
|
||||||||||||||||
Revenues:
|
||||||||||||||||||||||||
Net
sales
|
$ | - | 80,690 | $ | 80,690 | |||||||||||||||||||
Cost
of sales
|
(129,815 | ) | (129,815 | ) | ||||||||||||||||||||
Gross
margin
|
(49,125 | ) | (49,125 | ) | ||||||||||||||||||||
Operating
expenses:
|
||||||||||||||||||||||||
Advertising
& promotion
|
- | 248,999 | 248,999 | |||||||||||||||||||||
Bad
debt
|
812 | 812 | ||||||||||||||||||||||
Bank
charges
|
1,547 | 1,547 | ||||||||||||||||||||||
Salaries
& labor
|
19,215 | 19,215 | ||||||||||||||||||||||
Depreciation
and amortization
|
1,521 | 1,521 | ||||||||||||||||||||||
Insurance
|
2,649 | 2,649 | ||||||||||||||||||||||
Information
technology
|
12,979 | 12,979 | ||||||||||||||||||||||
Travel,
meetings and entertainment
|
23,845 | 23,845 | ||||||||||||||||||||||
Occupancy,
telephone and utilities
|
8,175 | 8,175 | ||||||||||||||||||||||
Office
and warehouse supplies
|
11,962 | 11,962 | ||||||||||||||||||||||
Professional
fees
|
7,000 | 9,674 | 16,674 | |||||||||||||||||||||
Repairs
and maintenance
|
- | - | ||||||||||||||||||||||
Other
general and administrative
|
4,233 | 840 | 5,073 | |||||||||||||||||||||
Total
operating expenses
|
11,233 | 342,218 | 353,451 | |||||||||||||||||||||
Operating
loss
|
(11,233 | ) | (391,343 | ) | (402,576 | ) | ||||||||||||||||||
Extraordinary
gain
|
2,357 | 2,357 | ||||||||||||||||||||||
Interest
income
|
- | 14 | 14 | |||||||||||||||||||||
Interest
expense
|
- | (1,300 | ) | (1,300 | ) | |||||||||||||||||||
Net
loss
|
$ | (8,876 | ) | (392,629 | ) | $ | (401,505 | ) |
See notes
to pro forma combined financial statements
3
Tone in
Twenty
Pro Forma
Combined Statement of Operations
(Unaudited)
Three
months ended November 30, 2009
|
Three
months ended September 30, 2009
|
Pro
Forma Adjustments (1)
|
||||||||||||||||||||||
Tone
in Twenty
|
Muscle
Pharm LLC
|
(2 | ) | (3 | ) | (4 | ) |
Pro
Forma Combined
|
||||||||||||||||
Revenues:
|
||||||||||||||||||||||||
Net
sales
|
$ | - | 198,637 | $ | 198,637 | |||||||||||||||||||
Cost
of sales
|
(346,713 | ) | (346,713 | ) | ||||||||||||||||||||
Gross
margin
|
(148,076 | ) | (148,076 | ) | ||||||||||||||||||||
Operating
expenses:
|
||||||||||||||||||||||||
Advertising
& promotion
|
- | 359,980 | 359,980 | |||||||||||||||||||||
Bad
debt
|
(1,669 | ) | (1,669 | ) | ||||||||||||||||||||
Bank
charges
|
12,272 | 12,272 | ||||||||||||||||||||||
Salaries
& labor
|
83,250 | 83,250 | ||||||||||||||||||||||
Depreciation
and amortization
|
1,656 | 1,656 | ||||||||||||||||||||||
Insurance
|
3,512 | 3,512 | ||||||||||||||||||||||
Information
technology
|
5,287 | 5,287 | ||||||||||||||||||||||
Travel,
meetings and entertainment
|
29,363 | 29,363 | ||||||||||||||||||||||
Occupancy,
telephone and utilities
|
7,199 | 7,199 | ||||||||||||||||||||||
Office
and warehouse supplies
|
5,993 | 5,993 | ||||||||||||||||||||||
Professional
fees
|
5,020 | 66,454 | 71,474 | |||||||||||||||||||||
Repairs
and maintenance
|
799 | 799 | ||||||||||||||||||||||
Other
general and administrative
|
265 | 478 | 743 | |||||||||||||||||||||
Total
operating expenses
|
5,285 | 574,574 | 579,859 | |||||||||||||||||||||
Operating
loss
|
(5,285 | ) | (722,650 | ) | (727,935 | ) | ||||||||||||||||||
Interest
income
|
- | - | - | |||||||||||||||||||||
Interest
expense
|
- | (6,348 | ) | (6,348 | ) | |||||||||||||||||||
Net
loss
|
$ | (5,285 | ) | (728,998 | ) | $ | (734,283 | ) |
See notes
to pro forma combined financial statements
4
Tone in
Twenty
Notes to
Pro Forma Combined Financial Statements (Unaudited)
(1) The
Exchange Transaction is deemed to be a reverse acquisition. In accordance with
the Accounting and Financial Reporting Interpretations and Guidance provided by
the staff of the U.S. Securities and Exchange Commission, Tone in Twenty (the
legal acquirer) is considered the accounting acquiree and Muscle Pharm (the
legal acquiree) is considered the accounting acquirer. The consolidated
financial statements of the combined entity will in substance be those of Muscle
Pharm, with the assets and liabilities, and revenues and expenses, of Tone in
Twenty being included effective from the date of consummation of the Exchange
Transaction. Tone in Twenty is deemed to be a continuation of the business of
Muscle Pharm. The outstanding stock of Tone in Twenty prior to the Exchange
Transaction will be accounted for at its net book value and no goodwill will be
recognized.
(2) To
reflect the issuance of 26,000,000 shares of common stock for all the issued and
outstanding equity and voting interests of Muscle Pharm members.
(3) To
reflect the purchase and cancellation of 366,666 of common stock owned by the
Company's President for $25,000 to be paid by Muscle Pharm.
(4) To
reflect the elimination of Tone in Twenty's deficit accumulated during the
development stage, and to reflect the operating entity's (Muscle Pharm)
accumulated operating deficits as the combined entity's accumulated
deficit.
5